NASDAQ:SNOA Sonoma Pharmaceuticals - SNOA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.64 +0.01 (+0.61%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.58▼$1.7050-Day Range$1.01▼$2.0252-Week Range$1.00▼$4.25Volume233,758 shsAverage Volume5.68 million shsMarket Capitalization$5.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Sonoma Pharmaceuticals (NASDAQ:SNOA) StockSonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.Read More Receive SNOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNOA Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comSonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South KoreaJanuary 25, 2023 | marketwatch.comSonoma Pharma Shares Rise 82% After Pricing Agreement for Microcyn Rx ProductsFebruary 4, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 25, 2023 | benzinga.comThese Four Companies Are Attracting Investors Following Recent NewsJanuary 25, 2023 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn Rx ProductsJanuary 25, 2023 | investorplace.comWhy Is Sonoma Pharmaceuticals (SNOA) Up 70% Today?January 25, 2023 | finance.yahoo.comSonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx ProductsJanuary 4, 2023 | finance.yahoo.comSonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical SpasFebruary 4, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 17, 2022 | finance.yahoo.comSonoma Pharmaceuticals Second Quarter 2023 Earnings: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)November 15, 2022 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial ResultsNovember 15, 2022 | finance.yahoo.comSonoma Pharmaceuticals Reports Second Quarter 2023 Financial ResultsOctober 27, 2022 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United StatesOctober 27, 2022 | finance.yahoo.comSonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United StatesOctober 6, 2022 | finance.yahoo.comSonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, GermanyAugust 13, 2022 | seekingalpha.comSonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99MAugust 11, 2022 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports First Quarter 2023 Financial ResultsAugust 11, 2022 | finance.yahoo.comSonoma Pharmaceuticals Reports First Quarter 2023 Financial ResultsAugust 2, 2022 | finance.yahoo.comSonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical SupplyJuly 13, 2022 | finanznachrichten.deSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial ResultsJuly 13, 2022 | finance.yahoo.comSonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial ResultsJune 1, 2022 | seekingalpha.comSonoma gains on new U.S. EPA designation for disinfectantJune 1, 2022 | finance.yahoo.comSonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19May 4, 2022 | seekingalpha.comSonoma, XORTX top healthcare gainers; Spero, Semler Scientific lead losers' packMay 3, 2022 | investorplace.comWhy Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?May 3, 2022 | uk.investing.comHere's How PayPal Helped Trigger EU Antitrust Allegations Against AppleMay 3, 2022 | morningstar.comThinking about buying stock in Sonoma Pharmaceuticals, Chegg, SOS, Redbox Entertainment, or Better Therapeutics?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SNOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNOA Company Calendar Last Earnings11/14/2022Today2/04/2023Next Earnings (Estimated)2/10/2023Fiscal Year End3/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNOA CUSIPN/A CIK1367083 Webwww.sonomapharma.com Phone(800) 759-9305Fax707-283-0551Employees14Year Founded1999Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,090,000.00 Net Margins-46.28% Pretax Margin-48.46% Return on Equity-61.54% Return on Assets-30.50% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio2.66 Sales & Book Value Annual Sales$12.63 million Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.58Miscellaneous Outstanding Shares3,100,000Free Float2,810,000Market Cap$5.08 million OptionableNot Optionable Beta1.19 Social Links Key ExecutivesAmy M. TromblyChief Executive Officer & DirectorBruce ThorntonChief Operating Officer & SecretaryChad WhiteChief Financial OfficerKey CompetitorsNeuroBo PharmaceuticalsNASDAQ:NRBOPainReformNASDAQ:PRFXPetros PharmaceuticalsNASDAQ:PTPIHistogenNASDAQ:HSTONovaBay PharmaceuticalsNYSE:NBYView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 7,308 shares on 11/15/2022Ownership: 0.593%View All Institutional Transactions SNOA Stock - Frequently Asked Questions How have SNOA shares performed in 2023? Sonoma Pharmaceuticals' stock was trading at $1.12 on January 1st, 2023. Since then, SNOA stock has increased by 46.4% and is now trading at $1.64. View the best growth stocks for 2023 here. When is Sonoma Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 10th 2023. View our SNOA earnings forecast. How were Sonoma Pharmaceuticals' earnings last quarter? Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its quarterly earnings results on Monday, November, 14th. The company reported ($0.19) EPS for the quarter. The business earned $3.33 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 46.28% and a negative trailing twelve-month return on equity of 61.54%. What other stocks do shareholders of Sonoma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT). What is Sonoma Pharmaceuticals' stock symbol? Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA." How do I buy shares of Sonoma Pharmaceuticals? Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sonoma Pharmaceuticals' stock price today? One share of SNOA stock can currently be purchased for approximately $1.64. How much money does Sonoma Pharmaceuticals make? Sonoma Pharmaceuticals (NASDAQ:SNOA) has a market capitalization of $5.08 million and generates $12.63 million in revenue each year. The company earns $-5,090,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. How can I contact Sonoma Pharmaceuticals? Sonoma Pharmaceuticals' mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The official website for the company is www.sonomapharma.com. The company can be reached via phone at (800) 759-9305, via email at dmcfadden@sonomais.com, or via fax at 707-283-0551. This page (NASDAQ:SNOA) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.